•
Home
•
Top Stories
Office Location
Contact Us
Information Request
Press Releases
Events & Presentations
Email Alerts
Clinical Pipeline
Remoxy
PTI-202
PTI-721
Monoclonal Antibody
Factor IX Replacement
Corporate Overview
Corporate Governance
Stock Information
Financial Information
FAQ
Management
Board of Directors
Publications
Code of Ethics
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.
PUBLICATIONS
Melanoma Paper
Format
Dead Cells in Melanoma Tumors Provide Abundant Antigen for Targeted Delivery of Ionizing Radiation by a mAb to Melanin
-- PNAS, October 2004
Hemophilia Paper
Format
Site-specific genomic integration produces therapeutic Factor IX levels in mice
-- Nature Biotechnology, November 2002
Posters
Format
Remoxy Phase III
-- IASP, 2008
Remoxy Alcohol Interaction
-- IASP, 2008
Remoxy
-- APS, 2006
Neuropathic Pain
-- APS, 2006
Journal Articles and Book Chapters
Format
Naloxone’s Pentapeptide Binding Site on Filamin A Blocks Mu Opioid Receptor–Gs Coupling and CREB Activation of Acute Morphine
-- PLoS, 1/2009
High-Affinity Naloxone Binding to Filamin A Prevents Mu Opioid Receptor–Gs Coupling Underlying Opioid Tolerance and Dependence
-- PLoS, 2/2008
G[beta][gamma] that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein.
-- Journal of Neurobiology, 10/2006
Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in Mu opioid receptor -- G protein coupling and G beta gamma signaling.
-- Neuroscience, 8/2005
Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats.
-- Psychopharmacology, 7/2005